Paradigm Biopharma Advances Phase 3 OA Trial, Secures $41M Funding, Expands Pipeline

• Global Phase 3 trial for iPPS initiated with 27 sites activated
• FDA accepted final Phase 3 protocol without comment
• Raised A$16 million equity and secured US$27 million convertible note
• Acquired Pentacoxib™, an oral PPS + COX-2 inhibitor for early-stage OA